SequelSEC

Viskase Holdings, Inc. VISK

Biological Products, (No Diagnostic Substances) · CIK 0000727510 · Fiscal year ends 1231

Revenue
$191.47M
Fiscal year ended 2025-06-30
Operating income
-$17.71M
Fiscal year ended 2025-06-30
Free cash flow
Unavailable
Fiscal year ended 2025-06-30

Viskase Holdings, Inc. (VISK) reported revenue of $191.47M and net income of -$33.65M for the fiscal year ended 2025-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Viskase Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Viskase Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Revenue$191.47M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$17.71M
Net income-$33.65M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$20.39M
Income tax expense$13.28M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Viskase Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Cash & equivalents$44.29M
Total assets$44.78M
Current assets$44.74M
Total liabilitiesUnavailable
Current liabilities$803.00K
Total equity incl. NCI$159.82M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$331.00K

Cash flow

Viskase Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Operating cash flow$3.00M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$16.83M
Net change in cash$3.84M
Stock-based compensationUnavailable
Common dividends paid$1.28M
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Viskase Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-9.2%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio55.71x
Revenue YoY growthUnavailable
Net margin-17.6%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VISK in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.